These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2908706)

  • 1. Neuropeptide-dopamine interactions. III. Cyclo(His-Pro) and persistence of dopaminergic supersensitivity on withdrawal from one year continuous neuroleptic treatment.
    Prasad C
    Schizophr Res; 1988; 1(6):411-5. PubMed ID: 2908706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cyclo (Leu-Gly) on neurochemical indices of striatal dopaminergic supersensitivity induced by prolonged haloperidol treatment.
    Le Douarin C; Fage D; Scatton B
    Life Sci; 1984 Jan; 34(4):393-9. PubMed ID: 6694528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of prolyl-leucyl-glycinamide and cyclo(leucyl-glycine) on the supersensitivity of dopamine receptors in brain induced by chronic administration of haloperidol to rats.
    Bhargava HN
    Neuropharmacology; 1984 Apr; 23(4):439-44. PubMed ID: 6145116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice.
    Fukushiro DF; Carvalho Rde C; Ricardo VP; Alvarez Jdo N; Ribeiro LT; Frussa-Filho R
    Brain Res Bull; 2008 Sep; 77(2-3):124-8. PubMed ID: 18721669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of melatonin on behavioral dopaminergic supersensitivity.
    Abílio VC; Vera JA; Ferreira LS; Duarte CR; Martins CR; Torres-Leite D; Ribeiro Rde A; Frussa-Filho R
    Life Sci; 2003 May; 72(26):3003-15. PubMed ID: 12706487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of dopaminergic supersensitivity by a single dose of amphetamine.
    Haracz JL; Tseng LF
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Aug; 313(2):131-3. PubMed ID: 6106902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical neuroleptics suppress dopaminergic behavioral supersensitivity.
    Schremmer C; Morgenstern R; Fink H; Ott T
    Psychopharmacology (Berl); 1990; 100(3):399-403. PubMed ID: 1969173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of acute and long-term typical or atypical neuroleptics on morphine-induced behavioural effects in mice.
    Hollais AW; Patti CL; Zanin KA; Fukushiro DF; Berro LF; Carvalho RC; Kameda SR; Frussa-Filho R
    Clin Exp Pharmacol Physiol; 2014 Mar; 41(3):255-63. PubMed ID: 24471703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of buspirone on dopaminergic supersensitivity.
    Queiroz CM; Frussa-Filho R
    Life Sci; 1997; 61(4):371-82. PubMed ID: 9244363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
    Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
    Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic supersensitivity after neuroleptics: time-course and specificity.
    Muller P; Seeman P
    Psychopharmacology (Berl); 1978 Dec; 60(1):1-11. PubMed ID: 32574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropeptide-dopamine interactions. I. Dopaminergic mechanisms in cyclo(His-Pro)-mediated hypothermia in rats.
    Prasad C
    Brain Res; 1987 Dec; 437(2):345-8. PubMed ID: 3435841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function.
    Glenthøj B
    Psychopharmacology (Berl); 1993; 113(2):157-66. PubMed ID: 7855176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of neuroleptic-induced dopamine receptor supersensitivity by cyclo (Leu-Gly).
    Bhargava HN; Ritzmann RF
    Pharmacol Biochem Behav; 1980 Nov; 13(5):633-6. PubMed ID: 7443732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol.
    Hashimoto T; Baba S; Ikeda H; Oda Y; Hashimoto K; Shimizu I
    Eur J Pharmacol; 2018 Jul; 830():26-32. PubMed ID: 29684390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute buspirone abolishes the expression of behavioral dopaminergic supersensitivity in mice.
    Queiroz CM; Alcântara FB; Yagüe AM; Bibancos T; Frussa-Filho R
    Braz J Med Biol Res; 2002 Feb; 35(2):237-42. PubMed ID: 11847528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroleptic-induced supersensitivity and brain iron: I. Iron deficiency and neuroleptic-induced dopamine D2 receptor supersensitivity.
    Ben-Shachar D; Youdim MB
    J Neurochem; 1990 Apr; 54(4):1136-41. PubMed ID: 1968955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral evidence for dopamine receptor subsensitivity following chronic haloperidol.
    Lynch MR
    Neuropsychobiology; 1990-1991; 24(2):102-8. PubMed ID: 2151972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioural correlates of modified dopaminergic/anticholinergic responses following chronic treatment with neuroleptic agents of differing activity spectra.
    Costall B; Naylor RJ; Owen RT
    Eur J Pharmacol; 1978 Mar; 48(1):29-36. PubMed ID: 25189
    [No Abstract]   [Full Text] [Related]  

  • 20. Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats.
    Perry JC; Vital MA; Frussa-Filho R; Tufik S; Palermo-Neto J
    Eur Neuropsychopharmacol; 2004 Mar; 14(2):127-33. PubMed ID: 15013028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.